<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494767</url>
  </required_header>
  <id_info>
    <org_study_id>KGW108201</org_study_id>
    <nct_id>NCT00494767</nct_id>
  </id_info>
  <brief_title>Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs</brief_title>
  <official_title>An Exploratory Study to Evaluate Weight Loss, Body Composition Changes, Food Intake and Urine Glucose Excretion in Healthy Obese Subjects Over 8 Weeks of Dosing With GSK189075, GW869682 Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The drugs GSK189075 and GW869682 result in increased caloric losses. This study is
      investigating how if taken over 8 weeks that affects weight loss, food intake and the
      composition of the body. The body composition (fat,water, lean mass) is determined using a
      new investigational MR technology.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2006</start_date>
  <completion_date type="Actual">June 7, 2007</completion_date>
  <primary_completion_date type="Actual">June 7, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Body fat and fat-free mass as determined by a new investigational MR technique compared to 4C Model methodologies.</measure>
    <time_frame>Measurements at week 8 will be compared to measurements from Day -1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (caloric losses body weight, body composition, weight and hip circumference.)</measure>
    <time_frame>throughout study (Days 1-56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin levels in serum</measure>
    <time_frame>at several points during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug levels in blood over time (Day 42 PK parameters are AUC, Cmax, tmax)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>GW869682 1000 mg thrice daily (TID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive GW869682 1000 mg TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK189075 250 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive GSK189075 250 mg TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW869682-Placebo TID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive Placebo matching GW869682 for TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK189075-Placebo TID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive Placebo matching GSK189075 for TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW869682</intervention_name>
    <description>GW869682 tablet with a dose strength of 250 mg will be available for subjects</description>
    <arm_group_label>GW869682 1000 mg thrice daily (TID)</arm_group_label>
    <arm_group_label>GSK189075 250 mg TID</arm_group_label>
    <arm_group_label>GW869682-Placebo TID</arm_group_label>
    <arm_group_label>GSK189075-Placebo TID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK189075</intervention_name>
    <description>GSK189075 tablet with a dose strength of 250 mg will be available for subjects</description>
    <arm_group_label>GW869682 1000 mg thrice daily (TID)</arm_group_label>
    <arm_group_label>GSK189075 250 mg TID</arm_group_label>
    <arm_group_label>GW869682-Placebo TID</arm_group_label>
    <arm_group_label>GSK189075-Placebo TID</arm_group_label>
    <other_name>GW869682</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK189075-Placebo</intervention_name>
    <description>Placebo tablets to match GSK189075 250 mg will be available for subjects</description>
    <arm_group_label>GW869682 1000 mg thrice daily (TID)</arm_group_label>
    <arm_group_label>GSK189075 250 mg TID</arm_group_label>
    <arm_group_label>GW869682-Placebo TID</arm_group_label>
    <arm_group_label>GSK189075-Placebo TID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW869682-Placebo</intervention_name>
    <description>Placebo tablets to match GW869682 250 mg will be available for subjects</description>
    <arm_group_label>GW869682 1000 mg thrice daily (TID)</arm_group_label>
    <arm_group_label>GSK189075 250 mg TID</arm_group_label>
    <arm_group_label>GW869682-Placebo TID</arm_group_label>
    <arm_group_label>GSK189075-Placebo TID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  BMI of 30 - 40kg/m

          -  Females may be included if they are surgically sterile or post-menopausal

        Exclusion criteria:

          -  Change in body weight &gt;4% in the last 3 months

          -  History of eating disorders

          -  had bariatric surgical intervention for obesity

          -  have type I or II diabetes

          -  Thyroid disorder not under control

          -  Renal or hepatobiliary disease

          -  Excessive alcohol consumption

          -  Use of drugs of abuse

          -  donated of blood in the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 2GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/KGW108201?search=study&amp;search_terms=KGW108201#rs</url>
    <description>Results for study KGW108201 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>body composition</keyword>
  <keyword>obesity</keyword>
  <keyword>4C model</keyword>
  <keyword>hunger</keyword>
  <keyword>weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

